Last reviewed · How we verify

Pioglitazone + Alogliptin — Competitive Intelligence Brief

Pioglitazone + Alogliptin (Pioglitazone + Alogliptin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Thiazolidinedione + DPP-4 inhibitor combination. Area: Diabetes.

marketed Thiazolidinedione + DPP-4 inhibitor combination PPAR-γ and DPP-4 Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Pioglitazone + Alogliptin (Pioglitazone + Alogliptin) — Celltrion Pharm, Inc.. Pioglitazone improves insulin sensitivity by activating PPAR-γ, while alogliptin inhibits DPP-4 to increase incretin levels, together reducing blood glucose in type 2 diabetes.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Pioglitazone + Alogliptin TARGET Pioglitazone + Alogliptin Celltrion Pharm, Inc. marketed Thiazolidinedione + DPP-4 inhibitor combination PPAR-γ and DPP-4

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Thiazolidinedione + DPP-4 inhibitor combination class)

  1. Celltrion Pharm, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pioglitazone + Alogliptin — Competitive Intelligence Brief. https://druglandscape.com/ci/pioglitazone-alogliptin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: